Drug intelligence / Profile preview

Restylane Sub Q

Development stage: Unknown
Lead developer: Galderma
Administration: Subcutaneous

Overview

Restylane Sub Q is a dermal filler composed of non-animal stabilized hyaluronic acid (NASHA) gel, specifically designed for deep subcutaneous or supraperiostal injection to restore facial volume and enhance contours. Developed by Q-Med (a subsidiary of Galderma), it features larger gel particles (approximately 1,000 particles/mL) compared to other products in the Restylane family, providing robust structural support. It is indicated for aesthetic procedures such as cheek and chin augmentation, midface rejuvenation, and the correction of facial asymmetry, as well as for medical conditions like HIV-associated facial lipoatrophy. The effects are non-permanent, typically lasting 12 months or longer.

Brand names: Restylane Sub QRestylane SubQ
Other names: NASHA gelnon-animal stabilized hyaluronic acid gel

Beyond the preview

Go deeper on Restylane Sub Q.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Restylane Sub Q.

Explore the full profile